Abstract
To achieve the World Health Organization hepatitis C virus (HCV) elimination targets, it is essential to increase access to treatment. Direct-acting antiviral (DAA) treatment can be provided in primary healthcare services (PHCS), improving accessibility, and, potentially, retention in care. Here, we describe our protocol for assessing the effectiveness of providing DAAs in PHCS, and the impact on the HCV care cascade. In addition, we reflect on the challenges of conducting a model of care study during a period of unprecedented change in HCV care and treatment. Consenting patients with HCV infection attending 13 PHCS in Australia or New Zealand are randomized to receive DAA treatment at the local tertiary institution (standard care arm), or their PHCS (intervention arm). The primary endpoint is the proportion commenced on DAAs and cured. Treatment providers at the PHCS include: hepatology nurses, primary care practitioners, or, in two sites, a specialist physician. All PHCS offer opioid substitution therapy. The Prime Study is the first real-world, randomized, model of care study exploring the impact of community provision of DAA therapy on HCV-treatment uptake and cure. Although the study has faced challenges unique to this per...Continue Reading
References
Jun 3, 2011·The New England Journal of Medicine·Sanjeev AroraClifford Qualls
Aug 2, 2011·Lancet·Paul K NelsonLouisa Degenhardt
Jan 17, 2012·The American Journal of Drug and Alcohol Abuse·R Douglas BruceFrederick L Altice
Feb 9, 2012·Medical Care·Geoffrey M CurranCheryl Stetler
Jan 31, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andrew R LloydDenise Monkley
Apr 5, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Natasha K MartinMatthew Hickman
Apr 26, 2013·Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie·Adam Isaiah NewmanRon Shore
Aug 2, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Carla TreloarMarkus Backmund
Apr 10, 2014·Journal of Viral Hepatitis·G J DoreM Thursz
Apr 12, 2014·The New England Journal of Medicine·Stefan ZeuzemBarry Bernstein
Apr 12, 2014·The New England Journal of Medicine·Kris V KowdleyUNKNOWN ION-3 Investigators
Jun 8, 2014·Lancet·Ira M JacobsonMaria Beumont-Mauviel
Jul 6, 2014·PloS One·Baligh R YehiaVincent Lo Re
Jun 30, 2015·Annals of Internal Medicine·Soumitri BaruaLynn E Taylor
Nov 13, 2015·PloS One·Amanda J WadeMargaret E Hellard
Apr 15, 2016·The Medical Journal of Australia·Alexander J V Thompson
May 18, 2016·BMC Infectious Diseases·Amanda J WadeJoseph S Doyle
May 20, 2016·Gut·Nick ScottMargaret E Hellard
Aug 16, 2016·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S LaniniG Ippolito
Jan 28, 2017·Journal of Viral Hepatitis·J M TaitJ F Dillon
Feb 27, 2017·Journal of Substance Abuse Treatment·B L NortonC O Cunningham
Aug 9, 2017·Annals of Internal Medicine·Sarah KattakuzhyUNKNOWN ASCEND Providers
Aug 12, 2017·The International Journal on Drug Policy·Nick ScottMargaret E Hellard
May 8, 2018·Annals of Hepatology·Kendall R BeckMandana Khalili
Citations
Sep 1, 2019·Journal of Internal Medicine·J V LazarusJ F Dillon
Apr 23, 2020·Journal of Family Medicine and Primary Care·Mohit Bhatia, Ekta Gupta
Dec 24, 2019·The International Journal on Drug Policy·Anna Y PalmerNick Scott
Feb 19, 2021·Journal of Viral Hepatitis·Brendan L HarneyJoseph S Doyle